[96a5a0]: / output / allTrials / identified / NCT03706027_identified.json

Download this file

863 lines (863 with data), 38.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
{
"info": {
"nct_id": "NCT03706027",
"official_title": "Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Prospective Randomized Phase II Study",
"inclusion_criteria": "* Histological confirmation of non-small cell cancer will not be required as primary goal of this phase II trial is to look at toxicity. However, all primary non-small cell lung cancers otherwise of following types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified.\n* Eligible patients must have appropriate staging studies identifying them as specific subsets of AJCC stage I or II based on only one of the following combinations of TNM staging:\n* T1, N0, M0\n* T2 (≤ 5 cm), N0, M0\n* Patients with hilar or mediastinal lymph nodes ≤ 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with > 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. All patients with suspicious nodes will be evaluated for mediastinal and hilar staging with bronchoscopy and (if amenable) bronchoscopic biopsy (preferably navigational biopsy and/or endobronchial US guided biopsy).\n* Zubrod performance status 0-2 within 4 weeks of study entry.\n* Women of childbearing potential and male participants must use an effective contraceptive method.\n* Evaluations required at time of study entry:\n* History & Physical by a radiation oncologist within 4 weeks of study entry;\n* Vitals within 4 weeks of study entry;\n* Evaluation by a thoracic surgeon (either via clinical examination and/or input at multidisciplinary tumor board) prior to study entry;\n* PFTs: Routine spirometry, lung volumes, diffusion capacity, and arterial blood gases within 8 weeks prior to study entry;\n* CT Chest within 6 weeks of study entry (preferably with intravenous contrast, unless medically contraindicated) - to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on this CT;\n* Whole body positron emission tomography (PET) scan using FDG with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions within 6 weeks prior to study entry.\n* Informed consent signed by the subject and a member of the study team.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Patients with central tumors. Specifically; central location implies a tumor inside the zone of the proximal bronchial tree defined as a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi\n* Evidence of regional or distant metastases after appropriate staging studies.\n* Synchronous primary NSCLC.\n* Those with prior malignancy in the past 2 years other than non-melanomatous skin cancer or in situ cancer or thyroid cancer.\n* Previous lung or mediastinal radiotherapy.\n* Plans for the patient to receive concomitant antineoplastic therapy (including standard fractionated radiotherapy, chemotherapy, biological therapy, vaccine therapy, and surgery) while on this protocol.\n* Patients with active systemic, pulmonary or pericardial infection.\n* Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histological confirmation of non-small cell cancer will not be required as primary goal of this phase II trial is to look at toxicity. However, all primary non-small cell lung cancers otherwise of following types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified.",
"criterions": [
{
"exact_snippets": "Histological confirmation of non-small cell cancer will not be required",
"criterion": "histological confirmation of non-small cell cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "all primary non-small cell lung cancers otherwise of following types are eligible: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchioalveolar cell carcinoma, or non-small cell carcinoma not otherwise specified",
"criterion": "type of non-small cell lung cancer",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"squamous cell carcinoma",
"adenocarcinoma",
"large cell carcinoma",
"bronchioalveolar cell carcinoma",
"non-small cell carcinoma not otherwise specified"
]
}
]
}
]
},
{
"line": "* Eligible patients must have appropriate staging studies identifying them as specific subsets of AJCC stage I or II based on only one of the following combinations of TNM staging:",
"criterions": [
{
"exact_snippets": "appropriate staging studies",
"criterion": "staging studies",
"requirements": [
{
"requirement_type": "appropriateness",
"expected_value": true
}
]
},
{
"exact_snippets": "specific subsets of AJCC stage I or II",
"criterion": "AJCC stage",
"requirements": [
{
"requirement_type": "subset",
"expected_value": [
"I",
"II"
]
}
]
},
{
"exact_snippets": "TNM staging",
"criterion": "TNM staging",
"requirements": [
{
"requirement_type": "combination",
"expected_value": "only one"
}
]
}
]
},
{
"line": "* T1, N0, M0",
"criterions": [
{
"exact_snippets": "T1",
"criterion": "tumor size",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "T1"
}
]
},
{
"exact_snippets": "N0",
"criterion": "lymph node involvement",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "N0"
}
]
},
{
"exact_snippets": "M0",
"criterion": "metastasis",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "M0"
}
]
}
]
},
{
"line": "* T2 (≤ 5 cm), N0, M0",
"criterions": [
{
"exact_snippets": "T2 (≤ 5 cm)",
"criterion": "tumor size",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "T2"
},
{
"requirement_type": "size",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "cm"
}
}
]
},
{
"exact_snippets": "N0",
"criterion": "lymph node involvement",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "N0"
}
]
},
{
"exact_snippets": "M0",
"criterion": "distant metastasis",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "M0"
}
]
}
]
},
{
"line": "* Patients with hilar or mediastinal lymph nodes ≤ 1cm and no abnormal hilar or mediastinal uptake on PET will be considered N0. Patients with > 1 cm hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer. All patients with suspicious nodes will be evaluated for mediastinal and hilar staging with bronchoscopy and (if amenable) bronchoscopic biopsy (preferably navigational biopsy and/or endobronchial US guided biopsy).",
"criterions": [
{
"exact_snippets": "hilar or mediastinal lymph nodes ≤ 1cm",
"criterion": "hilar or mediastinal lymph nodes size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "cm"
}
}
]
},
{
"exact_snippets": "no abnormal hilar or mediastinal uptake on PET",
"criterion": "hilar or mediastinal uptake on PET",
"requirements": [
{
"requirement_type": "abnormality",
"expected_value": false
}
]
},
{
"exact_snippets": "> 1 cm hilar or mediastinal lymph nodes on CT",
"criterion": "hilar or mediastinal lymph nodes size on CT",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "cm"
}
}
]
},
{
"exact_snippets": "abnormal PET (including suspicious but non-diagnostic uptake)",
"criterion": "abnormal PET",
"requirements": [
{
"requirement_type": "abnormality",
"expected_value": true
}
]
},
{
"exact_snippets": "directed tissue biopsy of all abnormally identified areas are negative for cancer",
"criterion": "tissue biopsy of abnormally identified areas",
"requirements": [
{
"requirement_type": "cancer presence",
"expected_value": false
}
]
},
{
"exact_snippets": "suspicious nodes will be evaluated for mediastinal and hilar staging with bronchoscopy",
"criterion": "suspicious nodes evaluation",
"requirements": [
{
"requirement_type": "procedure",
"expected_value": "bronchoscopy"
}
]
},
{
"exact_snippets": "suspicious nodes will be evaluated for mediastinal and hilar staging with ... bronchoscopic biopsy",
"criterion": "suspicious nodes evaluation",
"requirements": [
{
"requirement_type": "procedure",
"expected_value": "bronchoscopic biopsy"
}
]
}
]
},
{
"line": "* Zubrod performance status 0-2 within 4 weeks of study entry.",
"criterions": [
{
"exact_snippets": "Zubrod performance status 0-2",
"criterion": "Zubrod performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "within 4 weeks of study entry",
"criterion": "timeframe for performance status assessment",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": "within 4 weeks of study entry"
}
]
}
]
},
{
"line": "* Women of childbearing potential and male participants must use an effective contraceptive method.",
"criterions": [
{
"exact_snippets": "Women of childbearing potential",
"criterion": "women of childbearing potential",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "male participants",
"criterion": "male participants",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "must use an effective contraceptive method",
"criterion": "contraceptive method usage",
"requirements": [
{
"requirement_type": "necessity",
"expected_value": true
}
]
}
]
},
{
"line": "* History & Physical by a radiation oncologist within 4 weeks of study entry;",
"criterions": [
{
"exact_snippets": "History & Physical by a radiation oncologist within 4 weeks of study entry",
"criterion": "History & Physical by a radiation oncologist",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": "within 4 weeks of study entry"
}
]
}
]
},
{
"line": "* Vitals within 4 weeks of study entry;",
"criterions": [
{
"exact_snippets": "Vitals within 4 weeks of study entry",
"criterion": "vitals",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 4 weeks of study entry"
}
]
}
]
},
{
"line": "* Evaluation by a thoracic surgeon (either via clinical examination and/or input at multidisciplinary tumor board) prior to study entry;",
"criterions": [
{
"exact_snippets": "Evaluation by a thoracic surgeon (either via clinical examination and/or input at multidisciplinary tumor board)",
"criterion": "evaluation by a thoracic surgeon",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* PFTs: Routine spirometry, lung volumes, diffusion capacity, and arterial blood gases within 8 weeks prior to study entry;",
"criterions": [
{
"exact_snippets": "Routine spirometry",
"criterion": "spirometry",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 8 weeks prior to study entry"
}
]
},
{
"exact_snippets": "lung volumes",
"criterion": "lung volumes",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 8 weeks prior to study entry"
}
]
},
{
"exact_snippets": "diffusion capacity",
"criterion": "diffusion capacity",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 8 weeks prior to study entry"
}
]
},
{
"exact_snippets": "arterial blood gases",
"criterion": "arterial blood gases",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 8 weeks prior to study entry"
}
]
}
]
},
{
"line": "* CT Chest within 6 weeks of study entry (preferably with intravenous contrast, unless medically contraindicated) - to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on this CT;",
"criterions": [
{
"exact_snippets": "CT Chest within 6 weeks of study entry",
"criterion": "CT Chest timing",
"requirements": [
{
"requirement_type": "timing",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "preferably with intravenous contrast, unless medically contraindicated",
"criterion": "intravenous contrast",
"requirements": [
{
"requirement_type": "preference",
"expected_value": "preferably"
},
{
"requirement_type": "contraindication",
"expected_value": false
}
]
},
{
"exact_snippets": "to include the entirety of both lungs, the mediastinum, liver, and adrenal glands",
"criterion": "CT Chest coverage",
"requirements": [
{
"requirement_type": "coverage",
"expected_value": [
"both lungs",
"mediastinum",
"liver",
"adrenal glands"
]
}
]
},
{
"exact_snippets": "primary tumor dimension will be measured on this CT",
"criterion": "primary tumor dimension measurement",
"requirements": [
{
"requirement_type": "measurement",
"expected_value": true
}
]
}
]
},
{
"line": "* Whole body positron emission tomography (PET) scan using FDG with adequate visualization of the primary tumor and draining lymph node basins in the hilar and mediastinal regions within 6 weeks prior to study entry.",
"criterions": [
{
"exact_snippets": "Whole body positron emission tomography (PET) scan using FDG",
"criterion": "whole body PET scan",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate visualization of the primary tumor",
"criterion": "visualization of primary tumor",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate visualization of ... draining lymph node basins in the hilar and mediastinal regions",
"criterion": "visualization of lymph node basins",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "within 6 weeks prior to study entry",
"criterion": "timing of PET scan",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Informed consent signed by the subject and a member of the study team.",
"criterions": [
{
"exact_snippets": "Informed consent signed by the subject",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
},
{
"exact_snippets": "Informed consent signed by ... a member of the study team",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed by study team member",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients with central tumors. Specifically; central location implies a tumor inside the zone of the proximal bronchial tree defined as a volume 2 cm in all directions around the proximal bronchial tree (carina, right and left main bronchi, right and left upper lobe bronchi, intermedius bronchus, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi",
"criterions": [
{
"exact_snippets": "central tumors",
"criterion": "tumor location",
"requirements": [
{
"requirement_type": "location",
"expected_value": "central"
}
]
},
{
"exact_snippets": "central location implies a tumor inside the zone of the proximal bronchial tree",
"criterion": "tumor location",
"requirements": [
{
"requirement_type": "location",
"expected_value": "inside the zone of the proximal bronchial tree"
}
]
},
{
"exact_snippets": "defined as a volume 2 cm in all directions around the proximal bronchial tree",
"criterion": "tumor location",
"requirements": [
{
"requirement_type": "distance from proximal bronchial tree",
"expected_value": {
"operator": "=",
"value": 2,
"unit": "cm"
}
}
]
}
]
},
{
"line": "* Evidence of regional or distant metastases after appropriate staging studies.",
"criterions": [
{
"exact_snippets": "Evidence of regional or distant metastases",
"criterion": "metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "after appropriate staging studies",
"criterion": "staging studies",
"requirements": [
{
"requirement_type": "completion",
"expected_value": true
}
]
}
]
},
{
"line": "* Synchronous primary NSCLC.",
"criterions": [
{
"exact_snippets": "Synchronous primary NSCLC",
"criterion": "synchronous primary NSCLC",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Those with prior malignancy in the past 2 years other than non-melanomatous skin cancer or in situ cancer or thyroid cancer.",
"criterions": [
{
"exact_snippets": "prior malignancy in the past 2 years",
"criterion": "prior malignancy",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 2,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "non-melanomatous skin cancer",
"criterion": "non-melanomatous skin cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "in situ cancer",
"criterion": "in situ cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "thyroid cancer",
"criterion": "thyroid cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Previous lung or mediastinal radiotherapy.",
"criterions": [
{
"exact_snippets": "Previous lung ... radiotherapy",
"criterion": "lung radiotherapy",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "Previous ... mediastinal radiotherapy",
"criterion": "mediastinal radiotherapy",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Plans for the patient to receive concomitant antineoplastic therapy (including standard fractionated radiotherapy, chemotherapy, biological therapy, vaccine therapy, and surgery) while on this protocol.",
"criterions": [
{
"exact_snippets": "Plans for the patient to receive concomitant antineoplastic therapy",
"criterion": "concomitant antineoplastic therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "standard fractionated radiotherapy",
"criterion": "standard fractionated radiotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "chemotherapy",
"criterion": "chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "biological therapy",
"criterion": "biological therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "vaccine therapy",
"criterion": "vaccine therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "surgery",
"criterion": "surgery",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients with active systemic, pulmonary or pericardial infection.",
"criterions": [
{
"exact_snippets": "active systemic ... infection",
"criterion": "systemic infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active ... pulmonary ... infection",
"criterion": "pulmonary infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active ... pericardial infection",
"criterion": "pericardial infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.",
"criterions": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "lactating women",
"criterion": "lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"line": "* Evaluations required at time of study entry:",
"criterions": []
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}